1-6 of 6
Erica Campagnaro, MD
Close
Save search
Sort by
Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Free
Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134558
Published: 2020
Journal Articles

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Niels W.C.J. van de Donk, MD PhD, Rakesh Popat, Jeremy Larsen, Monique C. Minnema, Sundar Jagannath, MD, Albert Oriol, Jeffrey Zonder, Paul G. Richardson, MD, Paula Rodriguez-Otero, MD PhD, Ashraf Z. Badros, MD, Edward Stadtmauer, Sara Bringhen, MD, Erica Campagnaro, MD, David S. Siegel, MD PhD, Barbara Gamberi, Mercedes Gironella Mesa, Pieter Sonneveld, MD PhD, Tuong Vi Nguyen, Antonia Di Micco, April Sorrell, Min Chen, Michael Amatangelo, Elisabeth Kueenburg, Sagar Lonial, MD FACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-137743
Published: 2020
Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Free
Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-143180
Published: 2020
Journal Articles

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

Free
Irene M. Ghobrial, M.D., Nikhil Munshi, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc, Marybeth Nelson, PA, Amy Sam, Kelly O’Connor, Brianna Harris, Diane Warren, Akari M. Dollard, Jacob Laubach, MD, Ravi Vij, MD, Erica Campagnaro, MD, Ann Birner, Virginia Dixon-Lipscomb, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood
Blood (2008) 112 (11): 3696.
https://doi.org/10.1182/blood.V112.11.3696.3696
Published: 2008
Journal Articles

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Free
Andrzej Jakubowiak, MD, PhD, Tara Kendall, PA, Ammar Al-Zoubi, MD, Yasser Khaled, MD, Shin Mineishi, MD, Christine Brozo, Erica Campagnaro, MD, Moshe Talpaz, Mark S. Kaminski, MD
Journal: Blood
Blood (2008) 112 (11): 3713.
https://doi.org/10.1182/blood.V112.11.3713.3713
Published: 2008
Journal Articles

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Free
Erica Campagnaro, MD, Rima Saliba, Ph.D, Karen Anderson, Ph.D, Linda Roden, MD, Floralyn Mendoza, BS, Ana Aleman, MD, Charles Cleeland, Ph.D, Donna Weber, MD, Jane Brown, RN, Sergio Giralt, MD
Journal: Blood
Blood (2005) 106 (11): 1771.
https://doi.org/10.1182/blood.V106.11.1771.1771
Published: 2005